期刊文献+

免疫组织化学临床病理应用与肿瘤分子意义 被引量:2

Immunohistochemical clinical pathological application and tumor molecular significance
下载PDF
导出
摘要 医学科技日新月异,20世纪70年代随着单克隆抗体技术的发展,在病理学上开展了免疫组织化学(IHC),其把人们从传统病理组织学(形态学)推向蛋白质水平(抗原、抗体的定性和定位),在现代病理诊断中的应用日益广泛,尤其在肿瘤诊断与鉴别中起着非常重要的作用,对于诊断肿瘤、肿瘤分类、判断预后产生了巨大的影响,扩展了对各种疾病及肿瘤形成过程的认识,提高了病理诊断与研究水平。近来肿瘤的分子病理诊断及靶向治疗的意义成为研究热点。 Medical technology is changing rapidly,in the 1970s with the development of monoclonal antibody technol-ogy,immunohistochemistry (IHC) is developed in pathology,IHC brings people from the traditional pathological histolo-gy (morphology) into protein levels (qualitative and positioning of antigen and antibody) and it is widely applied in-creasingly in modern pathological diagnosis,and plays a very important role in tumor diagnosis and differential and has a great influence on diagnosis of tumor,tumor classification,prognosis estimation,and expandes people’s understanding of the various diseases and tumor formation,improve the level of the pathological diagnosis and research.Recent molec-ular pathological diagnosis of tumor and the significance of targeted therapy becoms a hot research topic.
作者 管蕾
出处 《中国当代医药》 2014年第26期188-190,共3页 China Modern Medicine
关键词 免疫组织化学 肿瘤 肿瘤分子 靶向治疗 Immunohistochemistry Tumor Tumor molecular Targeted therapy
  • 相关文献

参考文献7

二级参考文献77

  • 1Perou CM, Sφrlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature, 2000, 406:747-752.
  • 2Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysis. Int J Cancer, 2005, 116:340-350.
  • 3Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist, 1998, 3:237-252.
  • 4Chevallier B, Heintzmann F, Mosseri V, et al. Prognostic value of estrogen and progesterone receptors in operable breast cancer:results of a univariate and multivariate analysis. Cancer, 1988, 62:2517 -2524.
  • 5Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer, 1998, 34:791-808.
  • 6Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol, 2005, 123:541-546.
  • 7Francis G, Beadle G, Thomas S, et al. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Pathology, 2006,38 : 391-398.
  • 8Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer, 1994, 73:2359-2365.
  • 9Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modem chemotherapy for patients with node-positive breast cancer. JAMA, 2006, 295 : 1658-1667.
  • 10Paik S, Bryant J, Park C, et al. EerbB2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptornegative breast cancer. J Nail Cancer Inst, 1998, 90:1361-1370.

共引文献82

同被引文献15

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部